Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia

Abstract

MicroRNAs (miRNAs) expression profiles were screened in plasma samples from pediatric patients with acute lymphoblastic leukemia (ALL) and healthy controls, using qRT-PCR-based TaqMan low-density miRNA arrays. MiR-652-3p (a circulating miRNA) was downregulated in new diagnosis (ND) patients compared with healthy controls. The levels of miR652-3p were restored in complete remission (CR) but were downregulated again in disease relapse (RE). The expression pattern of miR-652-3p was validated in bone marrow (BM) samples from other pediatric ALL patients. MiR-652-3p was significantly upregulated in BM when the patients (n=86) achieved CR, as compared with the matched ND samples (p<0.001). Moreover, the miR-652-3p levels in BM decreased again in two patients at RE. In addition, the lymphoblastic leukemia cell lines Reh and RS4:11 were found to have lower levels of miR-625-3p than the normal B-cell line. Overexpression of miR-652-3p using agomir increased the sensitivity to vincristine and cytarabine (all p<0.05) and promoted apoptosis (both p<0.05) in Reh and RS4:11 cells. In conclusion, the results suggested that a low level of miR-652-3p might be involved in the pathogenesis of pediatric ALL. Overexpression of miR-652-3p might suppress lymphoblastic leukemia cells, promoting apoptosis and increasing sensitivity to chemotherapeutic drugs.

MicroRNA‑652 inhibits the biological characteristics of esophageal squamous cell carcinoma by directly targeting fibroblast growth factor receptor 1

“…However, miR-652 transfection inhibits the acidity-induced epithelial-mesenchymal transition of pancreatic cancer cells in vitro (25). In pediatric acute lymphoblastic leukemia, upregulation of miR-652 improves the sensitivity to vincristine and cytarabine and induces apoptosis in vitro and in vivo (24). To the best of our knowledge, the biological functions of miR-652 in ESCC cells were not previously studied.…”

“…miR-652 is dysregulated in several different types of cancer. For example, miR-652 is upregulated in endometrial cancer tissues and cell lines (22)(23)(24)(25). Patients with endometrial cancer with increased expression levels of miR-652 often have reduced overall survival rates and experience earlier recur-rence compared with patients with lower expression levels of miR-652 (22).…”

“…miR-652 is also overexpressed in non-small cell lung cancer, and associated with lymph node metastasis, Tumor-Node-Metastasis stage and prognosis in non-small cell lung cancer (23). miR-652 expression is often decreased in pediatric acute lymphoblastic leukemia (24) and pancreatic cancer (25). Decreased expression levels of miR-652 are associated with pancreatic cancer stage, lymphatic invasion and metastasis (25).…”

“…miR-652 has been recognized as a cancer-associated miRNA in endometrial cancer (22), non-small cell lung cancer (23), pediatric acute lymphoblastic leukemia (24) and pancreatic cancer (25). However, the expression status and roles of miR-652 in ESCC as well as the molecular mechanisms involved remain largely unknown.…”

MicroRNA‑31 is a potential biomarker for screening B‑lymphoblastic leukemia in children

“…miRNAs have been demonstrated to be influential factors in the pathogenesis of B-ALL (15,16). Numerous studies have identified roles of miRNAs in the diagnosis, treatment, classification, prognosis and risk assessment of tumors (16)(17)(18). Studies have revealed that miRNAs are involved in the occurrence and development of acute leukemia (18,19).…”